JP2019518756A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518756A5
JP2019518756A5 JP2018564884A JP2018564884A JP2019518756A5 JP 2019518756 A5 JP2019518756 A5 JP 2019518756A5 JP 2018564884 A JP2018564884 A JP 2018564884A JP 2018564884 A JP2018564884 A JP 2018564884A JP 2019518756 A5 JP2019518756 A5 JP 2019518756A5
Authority
JP
Japan
Prior art keywords
crystal
former
sodium benzoate
disorder
benzoate compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018564884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518756A (ja
JP6958922B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/088045 external-priority patent/WO2017215593A1/en
Publication of JP2019518756A publication Critical patent/JP2019518756A/ja
Publication of JP2019518756A5 publication Critical patent/JP2019518756A5/ja
Application granted granted Critical
Publication of JP6958922B2 publication Critical patent/JP6958922B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018564884A 2016-06-13 2017-06-13 安息香酸ナトリウムの共結晶及びその使用 Active JP6958922B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349578P 2016-06-13 2016-06-13
US62/349,578 2016-06-13
PCT/CN2017/088045 WO2017215593A1 (en) 2016-06-13 2017-06-13 Co-crystals of sodium benzoate and uses thereof

Publications (3)

Publication Number Publication Date
JP2019518756A JP2019518756A (ja) 2019-07-04
JP2019518756A5 true JP2019518756A5 (enExample) 2019-10-17
JP6958922B2 JP6958922B2 (ja) 2021-11-02

Family

ID=60663996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018564884A Active JP6958922B2 (ja) 2016-06-13 2017-06-13 安息香酸ナトリウムの共結晶及びその使用

Country Status (13)

Country Link
US (2) US11008277B2 (enExample)
EP (1) EP3468944B1 (enExample)
JP (1) JP6958922B2 (enExample)
KR (1) KR102403048B1 (enExample)
CN (1) CN109563018A (enExample)
CA (1) CA3027297A1 (enExample)
DK (1) DK3468944T3 (enExample)
ES (1) ES2936094T3 (enExample)
FI (1) FI3468944T3 (enExample)
IL (1) IL263492B (enExample)
MX (1) MX2018015397A (enExample)
TW (1) TWI671287B (enExample)
WO (1) WO2017215593A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI736635B (zh) 2016-06-13 2021-08-21 心悅生醫股份有限公司 苯甲酸鋰之共晶及其用途
EP3713556A4 (en) * 2017-11-22 2021-10-20 Chieh-Hsin Lin BENZOIC ACID OR A SALT AND DERIVATIVE THEREOF FOR USE IN THE PREVENTION OR TREATMENT OF DEPRESSION
EA202192199A1 (ru) 2019-02-25 2021-12-17 Раш Юниверсити Медикал Сентер Композиции, содержащие коричную кислоту, и способы их применения
WO2021245697A1 (en) 2020-06-01 2021-12-09 Celagenex Research (India) Pvt. Ltd. Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498989A (en) 1969-04-16 1970-03-03 American Home Prod Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
US3870715A (en) 1972-03-09 1975-03-11 Nikolaus R Hansl Substituted amino ethyl meta benzoic acid esters
US4041174A (en) 1974-08-16 1977-08-09 Rom-Amer Pharmaceuticals, Ltd. Method of treating depression
US4731379A (en) * 1983-12-07 1988-03-15 H.S.C. Corporation Flea eradicator
US5204356A (en) 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
GB8819494D0 (en) 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
CA2058455A1 (en) * 1990-12-21 1992-06-22 Mark W. Collison Synergistic effect of lantibiotics in combination with selected agents against gram positive bacteria
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
FR2700117B1 (fr) 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
DE4340273A1 (de) 1993-11-26 1995-06-01 Karla Dr Lehmann Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
US5441981A (en) * 1994-01-27 1995-08-15 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing a halogenated acetophenone and an organic acid
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
DE19925425A1 (de) * 1999-06-02 2000-12-07 Wessollek Heimo Mittel zur Entkeimung bzw. keimreduzierenden Gestaltung von Reinigungs-, Sanitär- und Toilettenartikeln sowie kosmetischen Artikeln, Körperpflegeartikeln und dergleichen verkeimungsgefährdeten Gegenständen
WO2001041707A2 (en) 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
MXPA03001337A (es) 2000-08-14 2005-06-30 Teva Pharma Preparacion de risperidona.
JP2004537275A (ja) 2001-01-16 2004-12-16 ジェンセット D−アミノ酸オキシダーゼおよびd−アスパラギン酸オキシダーゼのアンタゴニストを使用するcns障害の処置
US20030185754A1 (en) 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US20070053976A1 (en) 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
AU2003274353B2 (en) 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
CA2798615A1 (en) * 2003-01-21 2004-08-05 Aptuit (West Lafayette), Llc Novel cocrystallization of hydrochloric acid salt of an active agent
JP5069905B2 (ja) * 2003-01-21 2012-11-07 アプテュイト (ウエスト ラファイエット)、エルエルシー 新規な共結晶化
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
WO2005000205A2 (en) 2003-06-02 2005-01-06 Samaritan Pharmaceuticals, Inc. Methods and compositions for modulating serum cortisol levels
ZA200605384B (en) 2003-12-29 2007-10-31 Sepracor Inc Benzo[D]isoxazol-3-OL DAAO inhibitors
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
CA2556870C (en) 2004-02-18 2014-01-28 Timothy J. Barberich Dopamine-agonist combination therapy for improving sleep quality
US20050250738A1 (en) 2004-05-06 2005-11-10 Mosher Gerold L Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
JP5017103B2 (ja) 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2505808A1 (en) * 2005-05-02 2006-11-02 Julie Danielle Globus Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans
WO2006129160A2 (en) 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
US20110045065A1 (en) 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
GB0603181D0 (en) 2006-02-17 2006-03-29 Merck Sharp & Dohme Treatment of neurodegenerative and psychiatric diseases
US20080045547A1 (en) * 2006-07-07 2008-02-21 Lippa Arnold S Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
US20080070984A1 (en) 2006-09-15 2008-03-20 Tran Pierre V Compositions and Methods of Treating Schizophrenia
US20100204204A1 (en) * 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions
US8071143B2 (en) * 2008-04-02 2011-12-06 Brandeis University Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
US20130338199A1 (en) 2008-07-11 2013-12-19 Uday Saxena Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
KR20110050549A (ko) * 2008-09-03 2011-05-13 버텍스 파마슈티칼스 인코포레이티드 공-결정 및 이를 포함하는 제약 제제
JP2010106001A (ja) * 2008-10-31 2010-05-13 Theravalues Corp Ppar活性化剤
ES2731228T3 (es) 2009-01-20 2019-11-14 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Acido benzoico o sales del mismo para mejorar la actividad de un producto farmacéutico
ES2860676T3 (es) 2010-07-23 2021-10-05 Gruenenthal Gmbh Sales o cocristales de 3- (3-dimetilamino-1-etil-2-metil-propil) -fenol
EP2688575B1 (en) 2011-03-24 2016-03-23 University of South Florida Lithium compositions
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
PH12012000132B1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
US9120766B2 (en) * 2011-10-21 2015-09-01 Amri Ssci, Llc Methods of making cocrystals
IN2014DN09031A (enExample) * 2012-03-30 2015-05-22 Nuformix Ltd
PL2986618T3 (pl) * 2013-04-19 2022-07-18 University Of South Florida Organiczne anionowe jonowe związki kokrystaliczne i kompozycje litu
EP2991999B1 (en) 2013-04-29 2019-05-08 Mapi Pharma Limited Dapagliflozin lactose co-crystal
PT3424920T (pt) * 2013-10-17 2020-07-07 Vertex Pharma Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk
JP6895752B2 (ja) * 2013-12-13 2021-06-30 コナリス リサーチ インスティチュート アーゲー ニコチン酸および/またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物
WO2015147742A1 (en) * 2014-03-24 2015-10-01 Kaohsiung Chang Gung Memorial Hospital Use of benzoic acid salt in the manufactue of a composition for preventing or treating dementia or mild cognitive impairment
CN103992320A (zh) * 2014-05-26 2014-08-20 南京工业大学 一种混悬结晶制备药物共晶的方法
WO2015183801A1 (en) * 2014-05-27 2015-12-03 R. J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
US9896429B2 (en) * 2014-05-27 2018-02-20 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
US20170354666A1 (en) * 2014-11-19 2017-12-14 Rush University Medical Center Compositions and methods for treating lysosomal disorders
RU2582962C1 (ru) 2014-12-23 2016-04-27 Ольга Алексеевна Громова Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты)
TWI736635B (zh) * 2016-06-13 2021-08-21 心悅生醫股份有限公司 苯甲酸鋰之共晶及其用途
WO2017218162A1 (en) 2016-06-14 2017-12-21 Aemerge Llc Hydrocarbon recycling of carbonizer hot gases
US10064833B2 (en) * 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US9877942B1 (en) * 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof
US20190076472A1 (en) * 2017-09-14 2019-03-14 CT Development One, LLC Hyperammonemia therapy for children suffering from urea cycle disorders
US10098861B1 (en) * 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof

Similar Documents

Publication Publication Date Title
EP3728215B1 (en) One-pot process for the preparation of racemic nicotine by reaction of ethyl nicotinate with n-vinylpyrrolidone in the presence of sodium ethanolate or potassium ethanolate or mixtures thereof
US9701702B2 (en) Metathesis catalysts and methods thereof
US8546500B2 (en) Complexes for use in metathesis reactions
JP2011517443A5 (enExample)
RU2010119458A (ru) 1,3,5-тризамещенное производное триазола
JP2018504437A5 (enExample)
JP2010529045A5 (enExample)
JP2009525312A5 (enExample)
JP2019523279A5 (enExample)
JP2019518757A5 (enExample)
CN104961733A (zh) 雷迪帕韦新晶型及其制备方法
JP6218077B2 (ja) 有機ホウ素化合物及びその製造方法
JP2019529553A5 (enExample)
JP2020507567A5 (enExample)
JPWO2013147216A1 (ja) (2−ヘテロアリールアミノ)コハク酸誘導体
RU2018146423A (ru) Сокристаллы бензоата лития и их применения
CN105820184A (zh) 一种4-苯氧基苯硼酸的制备方法
CN105199017A (zh) 一种Cs-CD-MOFs化合物及其制备方法
JP2011527340A5 (enExample)
CA2979121A1 (en) Stereoselective synthesis of enantiomers of 8-hydroxyquinoline derivati ves
RU2019100436A (ru) Сокристаллы бензоата натрия и их применения
JP2018090594A (ja) ロジウム触媒及びアミン化合物の製造法
CN107973768B (zh) 一步合成香豆素类化合物的方法
US11020730B2 (en) Halogen-containing metathesis catalysts and methods thereof
CN107098858A (zh) 一种环丙沙星和四氯对苯二甲酸共晶体的结构及其溶剂热制备方法